drugset / Trial / NCT07195097
Sildosin as a Male Contraceptive Non Hormonal
RandomizedParallel-groupOpen-labelPrevention
Summary
In all, 200 healthy, sexually active, fertile male candidates will be assigned 100 in silodosin group and 100 in placebo group. Males using other contraceptive methods will be excluded. Follow up data of total spermatozoa per ejaculate, semen volume and Post-ejaculation urinalysis after 2, 6 and 12 weeks of the studied groups will be recorded. The various side effects reported in the study groups after 12 weeks from the start of the study will be recorded.
Timeline
- Start
- 2025-09
- Primary completion
- 2025-11
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Silodosin | Unknown | 8 mg | Oral |
Indications
No indication recorded.